Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice
Science Advances · 11.07.2025 · 11 (28)
DOI: 10.1126/sciadv.adj0006 ↗Kurz gefasst
Fachartikel in der Zeitschrift Science Advances, erschienen am 11.07.2025. Verfasst von Desheng Cao und 10 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow Universit…. Hauptthemen laut MEDLINE: Choroidal Neovascularization, Gene Editing, CRISPR-Cas Systems, Nanoparticles. Die Arbeit wurde bisher 33-mal zitiert (Crossref) und nennt 69 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
As an important modality for choroidal neovascularization (CNV) treatment, intravitreal injection of vascular endothelial growth factor A (VEGFA) inhibitors suffers from undesired response rate, low patient compliance, and ocular damage. Here, dynamically covalent lipid nanoparticles (LNPs) were engineered to mediate VEGFA gene editing and CNV treatment by codelivering Cas9 mRNA (mCas9) and single guide RNA (sgRNA) targeting VEGFA (sgVEGFA). A library of lipidoids bearing iminoboronate ester linkage was developed via facile “one-pot” synthesis, and the top-performing lipidoid-A 4 B 3 C 7 was formulated into LNP-A 4 B 3 C 7 with the highest mRNA transfection efficiency. Inside the diseased retinal pigment epithelial cells, LNPs were dissociated upon H 2 O 2 -triggered lipidoid degradation, facilitating mRNA/sgRNA release to potentiate the gene editing efficiency. In laser-induced CNV mice, mCas9/sgVEGFA@LNP-A 4 B 3 C 7 after single intravitreal injection led to pronounced VEGFA disruption and CNV area reduction, outperforming the clinical anti-VEGF drug in eliciting sustained therapeutic effect. This study establishes a robust nonviral platform for mRNA delivery and genome editing and renders a promising strategy for CNV treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Institute of Functional Nano and Soft Materials (FUNSOM), Jiangsu Key Laboratory for Carbon-Based Functional Materials and Devices, Soochow University, Suzhou 215123, China.
- Department of Ophthalmology, The Second Affiliated Hospital of Soochow University, Suzhou 215004, China.
- Department of Ophthalmology, Lixiang Eye Hospital of Soochow University, Suzhou 215002, China.
ORCID-Profile: Desheng Cao, Junliang Zhu, Yang Guo, Yang Zhou, Yuanyuan Tu, Laiqing Xie, E Song, Manhui Zhu, Lichen Yin
Zitieren
APA
Cao, D., Zhu, J., Guo, Y., Zhou, Y., Zeng, J., Tu, Y., Zhao, Z., Xie, L., Song, E., Zhu, M., & Yin, L. (2025). Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice. Science Advances, 11(28). https://doi.org/10.1126/sciadv.adj0006
Vancouver
Cao D, Zhu J, Guo Y, Zhou Y, Zeng J, Tu Y, et al. Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice. Science Advances. 2025;11(28). doi:10.1126/sciadv.adj0006
BibTeX
@article{Cao2025,
author = {Cao, Desheng and Zhu, Junliang and Guo, Yang and Zhou, Yang and Zeng, Jia and Tu, Yuanyuan and Zhao, Ziyin and Xie, Laiqing and Song, E and Zhu, Manhui and Yin, Lichen},
title = {Dynamically covalent lipid nanoparticles mediate CRISPR-Cas9 genome editing against choroidal neovascularization in mice},
journal = {Science Advances},
year = {2025},
volume = {11},
number = {28},
doi = {10.1126/sciadv.adj0006}
}
EUVIMED